# Clinical Trial of CD123-targeted CAR-NK Therapy for Relapse/Refractory AML or BPDCN

> clinical trial · VERIFIED · 2026-08-28

Status: RECRUITING · Sponsor: Chongqing Precision Biotech Co., Ltd · Condition: AML (Acute Myeloid Leukemia)

- Company: Chongqing Precision Biotech Co., Ltd
- Sector: oncology
- Primary source: https://clinicaltrials.gov/study/NCT06690827

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.